• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A New Antipsychotic for Bipolar Depression

A New Antipsychotic for Bipolar Depression

July 30, 2020
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Lumateperone (Caplyta) just hit the pharmacy shelves with FDA approval in schizophrenia (see TCPR March 2020), and its manufacturer is pursuing further approval for bipolar depression. So far they’ve completed two phase III trials—one negative and one positive—and the positive one was presented in poster form by Suresh Durgam and colleagues at the International Society for Bipolar Disorders in June 2020.

The positive study was a controlled trial that randomized 377 patients to placebo or lumateperone 42 mg/day without titration (the same dose used in schizophrenia). Lumateperone began to separate from placebo after 1 week on the primary outcome measure (the Montgomery-Åsberg Depression Rating Scale), and those improvements continued throughout the 6-week trial (p < 0.0001 with intent-to-treat analysis). The main side effects were nausea and fatigue, but sleep also improved on this sedating antipsychotic. Consistent with the schizophrenia studies, the rates of akathisia and weight gain were low and not significantly different from placebo.

A strength of the study was the inclusion of bipolar II patients, who represented 20% of the sample. Although depression is more common in bipolar II than I, most antipsychotics have only been tested in bipolar I depression. Exceptions are quetiapine, which worked in bipolar II patients, and cariprazine (Vraylar), which did not. Lumateperone worked in the subset with bipolar II, but its effects were more pronounced in the bipolar I group.

Details on the negative trial were not available, but it was a smaller study (178 patients) with a similar design. Joseph Calabrese, one of the principal authors, reported that lumateperone still upheld a moderate effect size (0.56) when the results of the two studies were combined.

TCPR’s Take
Lumateperone is worth trying when other options for bipolar depression have failed, but insurance coverage will be difficult without FDA approval for that indication.

 

podcastsTo learn more, listen to our 8/31/20 podcast, “Existential Despair in Bipolar Depression: An Interview with Nassir Ghaemi.” Search for “Carlat” on your podcast store.
General Psychiatry
KEYWORDS antipsychotics bipolar-depression bipolar-ii bipolar_disorder caplyta lumateperone research-update
Aiken
Chris Aiken, MD.

Ask the Editor: Three Significant Food Interactions with ADHD Medications

More from this author
www.thecarlatreport.com
Issue Date: July 30, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Traumatic Brain Injury, TCPR, August 2020
Highlights From This Issue
A Guide to Online and Overseas Pharmacies
Assessing and Treating Traumatic Brain Injury
Silexan: A Novel Anxiolytic
Insight in Therapy: Still Relevant After All These Years
A New Antipsychotic for Bipolar Depression
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.